Navigation Links
Freezing Prostate Cancer Does a Man's Body Good
Date:3/9/2009

ions we make about treating prostate cancer," Onik said. "The data are unequivocal. If you're doing 'watchful waiting,' get mapped. If you're having radiation or hormone therapy or thinking about getting a 'nerve-sparing' radical prostatectomy, get mapped. If TRUS doesn't show all the cancer that's present, you're not going to have the proper treatment," said Onik.

With 3-D transperineal mapping, a grid placed over the perineum (the area of skin between the rectum and the scrotum) allows an interventional radiologist to accurately map the location of each biopsy core removed. The cores are taken through the skin rather than through the rectum, allowing many more cores to be removed -- about 50 compared to 10-12 in a TRUS biopsy. The mapping grid also allows the location of the tumor to be known much more precisely, allowing an interventional radiologist to cryoablate (freeze) only the tumor and not the whole prostate gland.

Controversy surrounds the treatment of prostate cancer, which usually grows slowly and initially remains confined to the prostate gland, said Onik. Growing evidence of overdetection and overtreatment in many men with low-risk tumors has led to a concept in the medical community of "watchful waiting" or observing a man's disease progression prior to initiating treatment. Many patients, however, feel uncomfortable with this strategy and may proceed to radical or aggressive treatment, said Onik. "When men must choose between 'watchful waiting' and high-morbidity whole-gland treatments (like surgery and radiotherapy), a lumpectomy-type treatment, which has so markedly changed the management of breast cancer for women, is a welcome 'middle ground' addition for those with prostate cancer," said Onik.

"Interventional cryoablation for prostate cancer is not experimental. This is a treatment option that doctors should discuss with their patients early on," emphasized Onik. Most people don'
'/>"/>

SOURCE Society of Interventional Radiology
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bay Area Women Sought for Egg Freezing Study
2. Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
5. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
8. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
9. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
10. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
11. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 1Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 2Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 3Clarient Reports Second Quarter Revenue Up 40 Percent 53673 1Clarient Reports Second Quarter Revenue Up 40 Percent 53673 2Clarient Reports Second Quarter Revenue Up 40 Percent 53673 3Clarient Reports Second Quarter Revenue Up 40 Percent 53673 4Clarient Reports Second Quarter Revenue Up 40 Percent 53673 5Clarient Reports Second Quarter Revenue Up 40 Percent 53673 6Clarient Reports Second Quarter Revenue Up 40 Percent 53673 7Clarient Reports Second Quarter Revenue Up 40 Percent 53673 8Clarient Reports Second Quarter Revenue Up 40 Percent 53673 9Clarient Reports Second Quarter Revenue Up 40 Percent 53673 10Cambrex Reports Second Quarter 2009 Results 53671 1Cambrex Reports Second Quarter 2009 Results 53671 2Cambrex Reports Second Quarter 2009 Results 53671 3Cambrex Reports Second Quarter 2009 Results 53671 4Cambrex Reports Second Quarter 2009 Results 53671 5Cambrex Reports Second Quarter 2009 Results 53671 6Cambrex Reports Second Quarter 2009 Results 53671 7Cambrex Reports Second Quarter 2009 Results 53671 8Cambrex Reports Second Quarter 2009 Results 53671 9Cambrex Reports Second Quarter 2009 Results 53671 10Cambrex Reports Second Quarter 2009 Results 53671 11Cambrex Reports Second Quarter 2009 Results 53671 12